Magnesium Sulfate and Trigger Points

Fayoum University

Status and phase

Not yet enrolling

Phase 2

Conditions

Myofascial Pain Syndrome

Treatments

Drug: masseter muscle

Drug: masseter and sternocleidomastoid muscle

Study type

Interventional

Funder types

Other

Identifiers

NCT06975813

1111

Details and patient eligibility

About

The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter &sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

definite diagnosis of myofascial pain
presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;
no history of any invasive procedures of the related masseter muscle.

Exclusion criteria

any painful conditions (other than myofascial trigger points) affecting the orofacial region
any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);
pregnancy and lactation